AI illustration · not actual product photoDetails from the source.
This catalogue entry records Oxytocin Acetate, 2 mg × 10 vials (SKU OT2), using the supplied source listing. The cited dossier describes: A specific FDA-labeled sterile synthetic oxytocin injection is used for labeled obstetric indications. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- OT2
- Source specification
- 2mg*10vials
- Source document
- PriceList(1).pdf, page 1
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
The catalogue uses the exact listing label “Oxytocin Acetate.” Oxytocin itself is a nine-amino-acid peptide hormone (a nonapeptide). The supplied label does not verify the exact salt, identity, purity, or contents of the listed OT2/OT5 vials; do not infer a specific vendor vial identity from the name.
Biological mechanism
Oxytocin binds the oxytocin receptor, a G-protein-coupled receptor. In uterine muscle, signaling principally through Gq/11 and phospholipase C increases intracellular calcium and promotes contraction. Oxytocin also contracts breast myoepithelial cells in the physiological milk-ejection reflex. Cellular/receptor mechanism does not establish efficacy for other proposed uses. [1] [2]
Research focus
A specific FDA-labeled sterile synthetic oxytocin injection is used for labeled obstetric indications. Separate human research has investigated intranasal oxytocin in social cognition and social functioning, including ASD; results have been mixed, and the large SOARS-B trial did not find significant benefit on its primary or generally its secondary outcomes. [2] [3]
Potential applications in the evidence
The FDA-labeled Pitocin formulation is indicated for specified obstetric uses: initiating or strengthening uterine contractions when medically indicated and producing contractions in the third stage of labor to control postpartum bleeding or hemorrhage. Intranasal oxytocin for social functioning, including ASD, has been investigated, but the evidence cited here does not establish benefit or an approved ASD use. Neither labeled uses nor research findings establish an application for these supplier-specific listings. [2] [3]
Human evidence
The Pitocin label documents obstetric indications for that specific FDA-labeled injectable formulation, not for the catalogue vials. In the 24-week randomized, placebo-controlled SOARS-B trial (290 children and adolescents with ASD), oxytocin did not significantly outperform placebo on the primary social-withdrawal measure or generally on secondary social/cognitive measures; adverse-event incidence and severity were similar between trial groups. The trial studied intranasal oxytocin, not OT2 or OT5. [2] [3]
Known and potential effects
FDA labeling for the approved injectable formulation reports maternal anaphylaxis, arrhythmias, hypertensive episodes, nausea, vomiting, uterine hypertonicity or tetanic contractions, uterine rupture, hemorrhage and severe water intoxication with convulsions or coma. Reported fetal/neonatal events include bradycardia, arrhythmias, low Apgar scores, jaundice, seizures, brain injury and death. These are label-reported effects for the named prescription formulation and obstetric context, not a verified adverse-effect profile for the unidentified catalogue vials. [2] A review of controlled intranasal studies through 2010 found no reliable short-term side-effect difference from placebo in those research settings, but noted case reports involving misuse or longer-term use. [4]
Safety and contraindications
The FDA label contraindicates antepartum use in specified circumstances, including uterine hyperactivity, certain fetal presentations or conditions in which vaginal delivery is contraindicated, fetal distress when delivery is not imminent, and hypersensitivity. It warns about conditions that predispose to uterine rupture and requires qualified hospital supervision for labeled labor use. This is not a complete safety assessment for an unknown product or route. The listing provides no manufacturer, batch, formulation source, regulatory jurisdiction, or product label from which to assess sterility, purity, excipients, contraindications, or route-specific risks. [2]
U.S. FDA / regulatory status
U.S. FDA labeling and the current DailyMed label establish that a specific sterile synthetic oxytocin injection, Pitocin, is a prescription drug with the obstetric uses stated in its label. Approval is product/formulation-specific and does not transfer to supplier-specific OT2 or OT5. The provided catalogue does not identify a manufacturer, lot, formulation source, jurisdiction, FDA application/approval number, or regulatory label; FDA approval of either exact vial therefore cannot be verified. Available evidence also does not establish that these items are compounded or research-only, so neither label is assigned. [2]
Evidence limitations
The catalogue’s exact source labels/specifications/prices are: OT2, Oxytocin Acetate, *10vials, 25 per 10 vials; OT5, Oxytocin Acetate, *10vials, 46 per 10 vials. The price list states no currency. These catalogue facts are not evidence of vial contents or quality. Receptor/cellular pharmacology should not be mistaken for clinical outcomes; the cited human ASD trial studied a different, manufactured intranasal formulation, and its findings cannot establish effects or safety for these vials. No cited human study evaluates OT2 or OT5. The exact product’s identity, salt, strength basis, purity, sterility, formulation, intended route, manufacturer and approval remain unverified.
Supporting sources
- PITOCIN—oxytocin injection: U.S. prescribing information National Library of Medicine, DailyMed (FDA drug labeling) · Official prescription drug label. Supports: Product-specific FDA-labeled obstetric indications, nonapeptide description, uterine mechanism, contraindications, warnings and reported adverse effects; supports distinction between the approved formulation and the unidentified listed vials.
- Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder New England Journal of Medicine · Primary randomized controlled clinical trial. Supports: Human ASD trial design and results, including lack of significant between-group differences over 24 weeks; formulation and adverse-event context.
- The Oxytocin Receptor: From Intracellular Signaling to Behavior Physiological Reviews / American Physiological Society · Peer-reviewed review. Supports: Oxytocin receptor classification and signaling pathways, including G-protein coupling and downstream cellular mechanisms; supports separating mechanistic evidence from proven clinical applications.
- A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research PubMed / National Library of Medicine; Psychoneuroendocrinology · Peer-reviewed systematic review. Supports: Scope and limitations of short-term intranasal human research safety findings and reported case reports involving misuse or longer-term use.